Clinically Significant EBV Infection in Allogeneic Stem Cell Transplanted Children Receiving Letermovir as Primary CMV Prophylaxis
Our study confirms letermovir's effectiveness against CMV. Yet, it also reports a high incidence of EBV reactivation and significant EBV infection, as well as a reduced GvHD prevalence in children receiving the drug. Our single-center, retrospective analysis has major limitations but raises a concern. Our findings require further validation in larger, multicenter, prospective studies.
Authors
- Anna Paisiou
- Aikaterini Kaisari (ORCID: https://orcid.org/0000-0002-5561-0397)
- Christina Oikonomopoulou (ORCID: https://orcid.org/0000-0003-2053-0191)
- Ioannis Grafakos
- Georgia Stavroulaki
- Michalis Kastamoulas (ORCID: https://orcid.org/0000-0001-5296-9962)
- Evgenios Goussetis
- Anna Komitopoulou (ORCID: https://orcid.org/0000-0001-9112-580X)
- E. Ioannidou
- Marina Letsiou
- Sofia Hante
Institutions
- Iaso Children’s Hospital (GR)
Publication Details
- Journal
- Transplant Infectious Disease
- Published
- 2025-04-20
- DOI
- https://doi.org/10.1111/tid.70032
- Citations
- 4
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 5.42